← Browse by Condition
Medical Condition
myelodysplastic syndrome
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 1
NCT04195633 Phase 2
Recruiting
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Enrollment
60 pts
Location
United States
Sponsor
Fred Hutchinson Cancer Center
NCT05031897 Phase 2
Recruiting
Two Step Haplo With Radiation Conditioning
Enrollment
63 pts
Location
United States
Sponsor
Thomas Jefferson University
NCT03471260 Phase 1, Phase 2
Recruiting
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Enrollment
96 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT06195891 Phase 1
Recruiting
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Enrollment
33 pts
Location
United States
Sponsor
City of Hope Medical Center
NCT01624805 Phase 2
Recruiting
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Enrollment
140 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT02115295 Phase 2
Recruiting
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Enrollment
508 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT03113643 Phase 1
Recruiting
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Enrollment
72 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute